www.freenome.com

Freenome Stock

Company Profile:

Freenome is a health technology company using accurate, accessible and non-invasive disease screenings to proactively treat cancer and other diseases at their most manageable stages. Freenome does this through a fusion of machine learning, biology and computer science.

Sign up for SecondMarket® to view the market and buy or sell Freenome Stock

Buy + Sell

24 Months 12 Months 6 Months

Freenome Stock Price Per Share

Freenome Funding

Date	Financing Round	Amount	Price per share*	Valuation*
Feb 15, 2024	Series F	254.00M	Price	Valuation
Jan 11, 2022	Series E	290.00M	Price	Valuation
Nov 22, 2021	Series D	243.00M	Price	Valuation
Aug 14, 2020	Series C	270.00M	Price	Valuation
Jun 24, 2019	Series B	160.00M	Price	Valuation
Aug 14, 2017	Series A	8.05M	Price	Valuation
Feb 23, 2017	Series A	63.95M	Price	Valuation
May 23, 2016	Series Seed	5.55M	Price	Valuation

*Access the PPS, Valuation details, and a wealth of other data by signing up. Source: Nasdaq Private Market Tape D®

See Freenome Valuations + Financials

*Sample data + company shown for illustrative purposes only

Gain insights Into Freenome Stock Valuation + Share Prices

View real-time Tape D® data on Freenome stock including most recent valuation and historical share price information.

Are you an institutional investor or employee shareholder? Sign up to the SecondMarket trading platform.

Get Started

Leverage Your Equity to Help Achieve More.

Freenome Management Team

CEO, Director

Mike Nolan
Co-Founder, Chief Growth Officer

Charles Roberts
Chief Scientific Officer

Jimmy Lin
Director

Ellen Hukkelhoven
Co-Founder, Director

Gabriel Otte
Director

Peter Kolchinsky
Director

Amir Nashat
Director

Randal Scott
Co-Founder, COO, Director

Riley Ennis
Director

Vijay Pande

Freenome Major Investors

Charles River Ventures (CRV)
T. Rowe Price
Catalio Capital Management
Novartis
Founders Fund
Section 32
Soleus Capital Management
Cormorant Capital
Rock Springs Capital
Data Collective
EcoR1 Capital
Janus Henderson
Kaiser Permanente Ventures
F. Hoffmann-La Roche
Bain Capital
Polaris Partners
Artis Ventures
Farallon Capital Management
RA Capital Management
Google
Asset Management Ventures
Spectrum 28 Capital
Innovation Endeavors
BrightEdge
Verily Life Sciences
Fidelity
Perceptive Advisors
Sands Capital Management
Roche Venture Fund
Colorectal Cancer Alliance
Third Kind Venture Capital
Cormorant Asset Management
Ridgeback Capital
DCVC
Andreessen Horowitz

Learn More About Freenome Stock

Buy Freenome Stock

Freenome stock does not trade on public stock exchanges. Freenome stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Freenome stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.

Learn more about the secondary market for private company shares on the investors page.

Sell Freenome Stock

Freenome Stock does not trade on public stock exchanges. In order to sell Freenome shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.

Learn more about NPM services for selling privately held stock on the Employee Shareholders page.

Read more about how to sell private company stock on the private secondary market:

Freenome Stock Price

Nasdaq Private Market estimates that Freenome price per share was $5.8 last month. This Freenome share value estimate (known as the Tape D™ price) is based on market activity, publicly-sourced valuation data, and other proprietary information. With Tape D premium for investors, you can get visibility into the Freenome share price today and the factors driving Freenome valuation estimates. Learn more about premium data here.

Read more about private company stock prices: Understanding the Bid-Ask Spread: How Buyers and Sellers Match on Price

Freenome Stock Ticker Symbol

There is no ticker symbol for Freenome stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.

Criteria to Sell Freenome Stock

Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Freenome stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.

Learn more about selling privately held stock on the Employee Shareholders page.

Read more about how to sell shares of a private company and eligibility for selling privately held stock:

Are You Eligible to Sell Private Company Stock?

Criteria to Buy or Invest in Freenome Stock

Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Freenome stock, you need to be an accredited entity or institutional investor.

Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.

Freenome Stock Settlement

Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.

To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.

Freenome IPO

Freenome is a private company and has not had an IPO. There is currently no Freenome IPO price. Get started to begin exploring the Nasdaq Private Market Tape D™ database and gain access to actionable data related to Freenome IPO.

Learn more about Tape D™ private company stock data for institutional investors on the on the Tape D™ Product Page.

Sign up for SecondMarket® to view the market and buy or sell Freenome Stock

Buy + Sell

*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.